Back to library
Cognitive

PE-22-28

A peptide derived from the spadin family that acts as a TREK-1 channel blocker. Shows antidepressant effects in research within 4 days (vs. 3 weeks for SSRIs).

5 mg vialHalf-life: ShortOnce dailyStandard · ≤10 mg/mL
Order: Coming soon

Overview

Clinical Benefits
  • Rapid antidepressant effects
  • Neurogenesis stimulation
  • Improved mood and motivation
  • Enhanced cognitive flexibility
Administration

Intranasal or subcutaneous injection

Drug class: neurotrophic peptide

Clinical Dosing

Typical dosage
50-200mcg
Starting dose
50mcg
Cadence
Once daily
Full titration schedule
PhaseDose
Weeks 1-250mcg daily (intranasal or subcutaneous)
Weeks 3+100-200mcg daily, cycle 4 weeks on / 2 weeks off

Safety Profile

Side effects
  • • Headache
  • • Nasal irritation (intranasal)
Contraindications
  • • Pregnancy
  • • Use with SSRIs (caution)

Cycling guidance

Off: 2 wks
Prevents TREK-1 receptor desensitization

Frequently asked questions

PE-22-28 is most commonly researched for: Rapid antidepressant effects, Neurogenesis stimulation, Improved mood and motivation, Enhanced cognitive flexibility.

Ready to build a protocol with PE-22-28?

LIA, our clinical reasoning engine, will build a personalized protocol — dosing, cadence, cycling, and safety checks — tailored to your goals and intake.

You’ll be asked to sign in first. Free tier includes the chat preview.

Information on this page is for educational purposes only and is not medical advice. Peptides should only be used under the supervision of a qualified healthcare provider.

Add to Home Screen

Install PeptideAI for quick access and an app-like experience.